Enliven Therapeutics Inc
(ELVN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2019 | 03-2019 | 03-2003 | 12-2002 | 09-2002 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -9,591 | -4,194 | -1,560 | 20,560 | 20,240 |
| Depreciation Amortization | N/A | N/A | 530 | 3,740 | 3,230 |
| Accounts payable and accrued liabilities | 764 | 931 | N/A | N/A | N/A |
| Other Working Capital | 1,744 | 1,692 | 370 | -1,820 | -2,500 |
| Other Operating Activity | -472 | -836 | 50 | -20,200 | -19,930 |
| Operating Cash Flow | $-7,555 | $-2,407 | $-610 | $2,280 | $1,040 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -81 | N/A | -30 | -1,640 | -1,530 |
| Net Acquisitions | N/A | N/A | 0 | 15,060 | 14,860 |
| Other Investing Activity | 0 | 0 | -1,490 | -7,320 | 460 |
| Investing Cash Flow | $-81 | $N/A | $-1,520 | $6,100 | $13,790 |
| Cash Flows From Financing Activities | |||||
| Other Financing Activity | 45,575 | 43,927 | 20 | 90 | 190 |
| Financing Cash Flow | $45,575 | $43,927 | $20 | $90 | $190 |
| Beginning Cash Position | 7,382 | 7,382 | 13,060 | 4,580 | 4,580 |
| End Cash Position | 45,321 | 48,902 | 10,940 | 13,060 | 19,610 |
| Net Cash Flow | $37,939 | $41,520 | $-2,110 | $8,470 | $15,030 |
| Free Cash Flow | |||||
| Operating Cash Flow | -7,555 | -2,407 | -610 | 2,280 | 1,040 |
| Capital Expenditure | -81 | N/A | N/A | N/A | N/A |
| Free Cash Flow | -7,636 | -2,407 | -610 | 2,280 | 1,040 |